TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life

TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life

Luca Richeldi,1 Pietro Schino,2 Elena Bargagli,3 Alberto Ricci,4 Alberto Rocca,5 Francesca Marchesani,6 Alfio Pennisi,7 Gianna Camiciottoli,8,9 Maria D’Amato,10 Francesco Macagno,1 Ulrica Scaffidi Argentina,11 Eleonora Ingrassia,11 Alessio Piraino11 1Division of Pulmonary Medicine, Fondazione Policl...

Full description

Bibliographic Details
Main Authors:	Richeldi L, Schino P, Bargagli E, Ricci A, Rocca A, Marchesani F, Pennisi A, Camiciottoli G, D'Amato M, Macagno F, Scaffidi Argentina U, Ingrassia E, Piraino A
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-02-01
Series:	International Journal of COPD
Subjects:	beclometasone/formoterol/glycopyrronium chronic obstructive pulmonary disease real-world fixed triple therapy adherence patient-reported outcomes
Online Access:	https://www.dovepress.com/tritrial-the-impact-of-fixed-triple-therapy-with-beclometasoneformoter-peer-reviewed-fulltext-article-COPD

Similar Items

Penggunaan Extrafine Beclometason Diproprionat/Formoterol Fumarat pada PPOK [Combined Extrafine Beclomethason Diproprionat/Formoteral Fumarat in COPD]
by: Sakinatus Syarifah, et al.
Published: (2019-05-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol
by: Richeldi L, et al.
Published: (2021-01-01)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
by: Sundeep Salvi, et al.
Published: (2022-01-01)

BDP/FF NEXThaler to Improve Asthma Control Status in the Real World: The NEWTON Study
by: Braido F, et al.
Published: (2023-10-01)

Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD
by: Ferguson GT, et al.
Published: (2018-03-01)

Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
by: Ratoe Suraya, et al.
Published: (2022-06-01)

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease
by: Omar Usmani, et al.
Published: (2021-10-01)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
by: Dhungana S, et al.
Published: (2017-08-01)

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
by: de Nigris E, et al.
Published: (2022-11-01)

The double bronchodilation era: new capabilities in a new drug delivery device
by: E. A. Orlova, et al.
Published: (2022-04-01)

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
by: Piotr Kuna, et al.
Published: (2022-08-01)

COPD and glycopyrronium responsiveness assessment: An appraisal
by: Parthasarathi Bhattacharyya, et al.
Published: (2023-01-01)

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
by: Henrik Watz, et al.
Published: (2020-04-01)

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
by: Brian R. Leaker, et al.
Published: (2019-06-01)

Eficácia do formoterol na reversão imediata do broncoespasmo Efficacy of inhaled formoterol in reversing bronchoconstriction
by: Adalberto Sperb Rubin, et al.
Published: (2006-06-01)

Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01)

Comparison of the effectiveness and safety of formoterol versus salmeterol in the treatment of patients with asthma: A systematic review and meta-analysis
by: Ashraf Velayati, et al.
Published: (2015-01-01)

Formation and Characterization of Beclomethasone Dipropionate Nanoparticles Using Rapid Expansion of Supercritical Solution
by: Mohsen Hosseinpour, et al.
Published: (2015-09-01)

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01)

SIMVASTATIN INDUCED HISTOMORPHOLOGICAL CHANGES IN SKELETAL MUSCLE FIBER OF RATS AND PROTECTIVE EFFECT OF FORMOTEROL COADMINISTRATION
by: Abdullah Qamar, et al.
Published: (2019-06-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts
by: Shigeo Muro, et al.
Published: (2021-06-01)

Comparison of Rapid Bronchodilatory Effects of Salmeterol and Formoterol in Patients with Moderate to Severe Asthma
by: Ebrahim Salehifar, et al.
Published: (2015-10-01)

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects
by: Satoru Inoue, et al.
Published: (2021-01-01)

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
by: Kaplan A, et al.
Published: (2019-01-01)

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease
by: Nalini Jayanthi, et al.
Published: (2022-08-01)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
by: Matera MG, et al.
Published: (2016-01-01)

Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK
by: Eklund O, et al.
Published: (2016-06-01)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
by: James Dean, et al.
Published: (2020-12-01)

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
by: Leif Bjermer, et al.
Published: (2017-12-01)

Metabolic changes of different high-resolution computed tomography phenotypes of COPD after budesonide–formoterol treatment
by: Wang C, et al.
Published: (2017-12-01)

Some aspects of application of the combination of formoterol and budesonide: what is changed?
by: A. A. Vizel, et al.
Published: (2019-12-01)

Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial
by: Arun Jenish J, et al.
Published: (2012-03-01)

The Effectiveness and Tolerability of Glycopyrronium for Patients with Chronic Obstructive Pulmonary Disease in a Clinical Setting: GLARE-Taiwan
by: Wei-Chang Huang, et al.
Published: (2022-10-01)

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
by: Tashkin DP
Published: (2020-11-01)

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach
by: Lakhotia B, et al.
Published: (2020-04-01)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
by: Miravitlles M, et al.
Published: (2016-08-01)

Impact of a Polymer-Based Nanoparticle with Formoterol Drug as Nanocarrier System In Vitro and in an Experimental Asthmatic Model
by: Buket Bakan, et al.
Published: (2023-11-01)